Heritage Medical Systems and AbbVie Ventures took part in genome editing technology developer Caribou Biosciences' first funding round in five years.

Funds managed by BlackRock added $40m to the $60m supplied for the drug development technology developer by investors including Novo, Evotec and Bristol Myers Squibb in May.

Biox Biosciences, Novo, Sanofi and Merck & Co are all in line to exit the immuno-oncology therapy developer, which has filed for a $100m initial public offering.

UC Berkeley-founded genome editing technology developer Caribou Biosciences has completed its first funding round in five years.

BlackRock has joined the University of Dundee spinout’s series C round, following a $60m first close in May last year.

Merck & Co is set to exit the genomic services and cancer diagnostics provider in an acquisition by Bio-Techne potentially sized at $320m.

Telus’ corporate venturing unit has led a $23.7m round for the Canadian online pharmacy as it seeks to take its coverage nationwide.

Inovio Pharmaceuticals spinoff Geneos Therapeutics will put the proceeds from the series A1 round towards advancing its liver cancer vaccine candidate.

Exploiting UChicago research, Reflexion is eyeing an expansion in Asia after receiving $40m in additional series D funding to bring the round to $150m.

Echo Health Ventures and Humana have returned to back the healthcare delivery provider’s series D round, which valued it at $1.7bn.